One of Accell’s clients, a developer of targeted therapeutics for various tumor types, starts 2 new Phase II clinical trials in Russia. Accell has been performing other clinical studies for this innovative cancer therapy since 2013. The client develops a method of targeted and timely delivery of therapeutic substances to diseased tissues without harming healthy cells. This method can significantly increase efficacy and safety of cancer treatment.

The first Phase II clinical study will test the new treatment for non-small cell cancer in 10 sites. The project team has initiated two sites out of ten in March and we are looking forward to recruiting first patients.

The second Phase II clinical study is planned to commence patient recruitment in July 2015 at 20 sites in Russia. The Russian sites will focus on treatment of patients suffering from head & neck cancer and cervical cancer.